The Cytogenomics Shared Resource provides services for characterizing the chromosomal status of malignant and nonmalignant human and animal cells. The wide array of assays offered are aimed at identifying numerical and structural genomic aberrations that have a potential role in the etiology of tumor development. The wide diversity of technologies offered ensures that investigators have the means of confirming novel findings by multiple independent methods. The approaches used are continuously evolving to include state-of-the-art techniques and now include whole-genome microarray analysis and multiple ligation-dependent probe amplification (MLPA) in addition to fluorescence in situ hybridization (FISH), G-banding, and spectral karyotyping (SKY). Conventional karyotyping is used to provide critical quality control for experiments using embryonic stem cells, induced pluripotent cells, and other genetically manipulated cells. The Shared Resource also partners with the University of Minnesota Genomics Center to provide an expanded range of molecular genomic services, including gene expression analysis, gene knockdown, epigenomics, sequencing, and mutation detection assays. To help investigators stay abreast ofthe advances in the field, the Cytogenomics Shared Resource provides consultation on experimental design, selection of the most appropriate techniques, and interpretation of data. Since the inception of this Resource in 2003, Betsy Hirsch, PhD, has been the Director and LeAnn Oseth has served as the Coordinator. Both have decades of experience in cancer cytogenetics

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-18
Application #
9002777
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-02-01
Budget End
2017-01-31
Support Year
18
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Guo, Zhijun; Johnson, Veronica; Barrera, Jaime et al. (2018) Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev 37:409-423
Scott, Milcah C; Temiz, Nuri A; Sarver, Anne E et al. (2018) Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. Cancer Res 78:326-337
Ho, Yen-Yi; Nhu Vo, Tien; Chu, Haitao et al. (2018) A Bayesian hierarchical model for demand curve analysis. Stat Methods Med Res 27:2038-2049
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Kaizer, Alexander M; Hobbs, Brian P; Koopmeiners, Joseph S (2018) A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. Biometrics 74:1082-1094
Li, Danni; Huang, Fangying; Zhao, Yingchun et al. (2018) Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study. Clin Proteomics 15:31
Sperduto, Paul W; Deegan, Brian J; Li, Jing et al. (2018) Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 20:1652-1660

Showing the most recent 10 out of 1013 publications